{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-092779","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.974625+00:00","generated_at":"2026-05-31T11:48:06.975369+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alector Q2 net loss $38.7M vs $1.4M income YoY; cash $503M, INVOKE-2 data on track for Q4 2024","bullets":["Net loss of $38.7M ($0.40 per share) compared to net income of $1.4M in Q2 2023.","Revenue fell to $15.1M from $56.2M YoY, primarily due to contract modifications on AL101 and AL002 programs.","Cash, cash equivalents and investments total $503.3M, expected to fund operations through 2026.","INVOKE-2 Phase 2 data for AL002 in early Alzheimer's disease anticipated in Q4 2024.","FDA feedback supports potential path to approval for latozinemab in FTD-GRN using biomarkers as confirmatory evidence."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-092779","json":"https://secwatch.observer/filing/0000950170-24-092779.json","markdown":"https://secwatch.observer/filing/0000950170-24-092779.md","text":"https://secwatch.observer/filing/0000950170-24-092779.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000095017024092779/0000950170-24-092779-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000095017024092779/alec-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:48:06.975369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}